Aardvark to unblind rare disease trial after FDA places full clinical hold; Alumis issues verdict on Acelyrin asset

Aardvark's rare disease candidate is under a full clinical hold by the FDA, which has paused all dosing and data collection.

The company says it intends to unblind the trial data despite the hold, indicating a next step in its development plan.

Alumis has released a decision regarding its Acelyrin asset, and brief mentions were made of Tenaya's TN-401 and Taiho's Inqovi, though no details were provided.